|
Pyritinol
Pyritinol has been used clinically in a wide range of disorders including cerebral circulatory disorders, alcoholism,
dyslexia, behavioral disorders in children, and stroke.
1. Pyritinol may be useful in various forms of dementia, head injury, stroke aftermath, coma, and cerebral circulatory disorders.
2. Pyritinol may be useful as an anti-brain aging, cognitive enhancing agent.
3. Pyritinol may be useful as an aid to improved memory, concentration, alertness and information processing in both young and old.
4. Pyritinol may be useful in Attention Deficit Disorder (ADD).
Pyritinol has been used following head injury and cerebral trauma. Pyritinol has reduced the normal high death rate in such cases and has rapidly returned coma patients to more or less normal waking
consciousness, even when the brain injuries were so severe the patient
ultimately died.
to
order
Pyritinol has the ability to enhance glucose transport through the
blood-brain barrier. Although the brain is usually less than 2% of total bodyweight, the brain
uses about 20% of the body's total energy production. Under normal, non-fasting conditions, the brain can only 'burn' glucose (sugar) for fuel. Unlike virtually all other body cells, nerve cells cannot use fat as an energy fuel. Brain cells also cannot store any significant amount of glucose - they are completely dependent upon a continuous
delivery of glucose from the blood, through the blood-brain barrier. Thus, brain glucose uptake is a major rate-limiting factor for crucial brain energy production. Pyritinol has the ability to increase glucose transport through the blood-brain barrier.
REFERENCES
1. K.Kitamura (1981)
"Therapeutic
Effect of Pyritinol on Sequelae of Head Injuries" J Int
Med Res 9, 215-21.
2. G. Dalle Ore et al
(1980) "The
Influence of the Administration of Pyritinol on the Clinical Course of
Traumatic Coma", J Neuroserg Sci 24, 1-8.
3. E.M. Lemmel (1993)
"Comparison
of Pyritinol and Auranofin in the Treatment of Rheumatoid Arthritis"
Br J Rheumatol 32, 375-82.
4. I. Hindmarch et al
(1990) "Psychopharmacalogical
Effects of Pyritinol in Normal Volunteers" Neuropsychobiol
24, 159-64.
5. A. Pavlik & J.
Pilar (1989) "Protection
of Cell Proteins Against Free-Radical Attack by Nootropic Drugs:
Scavenger Effects of Pyritinol Confirmed by Electron Spin Resonance
Spectroscopy" Nueropharmacol 28, 557-61.
6. R. Bradford & H.
Allen, Oxidology, Chula Vista, CA: R.W. Bradford Foundation, 1997.
A:p.65 B:p323 C:p.142 D:p.66 E:p.175.
7. S. Hoyer et al (1977)
"Effect
of Pyritinol-HCL on Blood Flow and Oxidative Metabolism of the Brain
in Patients with Dementia" Arzneim Forsch/Drug Res 27,
671-74.
8. R. Branconnier (1983)
"The Efficacy of the Cerebral Metabolic Enhancers in the
Treatment of Senile Dementia" Psychopharmacol
Bull 1983 Spring;19(2):212-9.
9. J. Elferink & B. de
Koster (1993) "Differential
Stimulation of Neutrophil Functions by Pyritinol" Int J
Immunopharmac 15, 641-46.
10. R. Huemer & J.
Challem, "The Natural Health Guide to Beating the Supergerms",
NY: PocketBooks, 1997. Pp.124-27.
11. H.-R. Olpe et al
(1985) "Locus Coeruleus as a Target for Psychogeriatric
Agents" Ann NY Acad Sci 444, 394-405.
12. G. Logue et al (1974)
"The Effects of Pyrithioxine on the Behavior and Intellectual
Functioning of Learning-Disabled Children" S.Afr Med J 48,
2245-46.
13. D. Lane O’Kelly
(1975) "Pyritinol in the Treatment of Chronic Alcoholics" J Int
Med Res 3, 323-27.
14. K. Fischhof et al
(1992) "Therapeutic
Efficacy of Pyritinol in Patients with Senile Dementia of the
Alzheimer Type (SDAT) and Multi-Infarct Dementia (MID)" Neuropsychobiol
26, 65-70.
15. A. Cooper & R.
Magnus (1980) "A
Placebo-Controlled Study of Pyritinol in Dementia" Pharmatherapeutica
2, 317-22.
|
